The Latest Breaking News from Cancer

IN FULL

Urgently referred patients are having to wait more than 28 days to receive a cancer diagnosis, exceeding NHS England’s target time

Cancer Research UK said its study shows that for people being diagnosed with cancer, things have been getting worse instead of better.

“My blood results were showing up as positive on a pregnancy test like I was two weeks pregnant. My first response was, ‘Is it mine?’” the patient said.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

On Wednesday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), benign, nerve sheath tumors.

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).

“That’s when the thought formed, ‘What do I actually do with my life?’ Am I just a human noise generator? Or am I actually telling stories?”

The scan only takes 15 to 20 minutes and could save the NHS money, researchers say.

Johnson Johnson (NYSE:JNJ) on Tuesday won regulatory approval for its drug delivery product Inlexzo to treat high-risk non-muscle invasive bladder cancer, a milestone Goldman Sachs says could launch “a powerful new product cycle” for the company's TAR-200 program.

The Scan pathway was created for people with non-specific symptoms, such as unexplained weight loss or fatigue.